Catalyst
Slingshot members are tracking this event:
Celgene (CELG) and Agios pharmaceuticals (AGIO) collaborative product IDHIFA (enasidenib), treatment for acute myeloid leukemia (AML) with IDH2 mutation, granted FDA priority review, with PDUFA decision due August 30
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2017
Occurred Source:
http://investor.agios.com/news-releases/news-release-details/fda-grants-approval-idhifar-first-oral-targeted-therapy-adult
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Acute Myeloid Leukemia, Idh2 Mutation, Idhifa, Enasidenib, Pdufa Date
